Clinical Trial Update: Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating encorafenib + cetuximab with or without binimetinib versus standard therapy in BRAF V600E-mutant metastatic colorectal cancer; safety l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Braf V600e-mutant Colorectal Cancer
• Colorectal Cancer

Drugs mentioned

• 5-FU/L-FU (5-fluorouracil)
• Binimetinib (binimetinib)
• Cetuximab (cetuximab)
• Encorafenib (encorafenib)
• Folinic acid (folinic acid)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Pfizer | Conditions: BRAF V600E-mutant Metastatic Colorectal Cancer | Phase 3 | Status: COMPLETED | Results posted: 2020-07-14